Serum myeloperoxidase in cystic fibrosis patients receiving systemic antibiotics

Scandinavian Journal of Infectious Diseases

Volumn 39, Issue 2, 2007, Pages 163-166

  Kohlhoff, Stephan ^a   Köhler, Elke ^b   Sollich, Veronika ^b  

^a SUNY Downstate Medical Center   (United States)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; MYELOPEROXIDASE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CYSTIC FIBROSIS; DIAGNOSTIC VALUE; DISEASE EXACERBATION; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; TIME SERIES ANALYSIS;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; CHILD; CYSTIC FIBROSIS; HUMANS; PEROXIDASE;

EID: 33847124898     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540600951259     Document Type: Article

References (23)

1. Ramsey, BW. (1997) Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med, 335, pp. 179-188.
2. Mohammed, JR, Mohammed, S., Pawluk, LJ, Bucci, DM, Baker, NR and Davis, B. (1988) Purification and cytotoxic potential of myeloperoxidase in cystic fibrosis sputum. J Lab Clin Med, 122, pp. 711-720.
3. Koller, DY, Urbanek, R. and Goetz, M. (1995) Increased degranulation of eosinophil and neutrophil granulocytes in cystic fibrosis. J Respir Crit Care Med, 152, pp. 629-633.
4. Koller, DY, Goetz, M., Eichler, I. and Urbanek, R. (1994) Eosinophilic activation in cystic fibrosis. Thorax, 49, pp. 496-499.
5. Koller, DY, Goetz, M., Wojnarowski, C. and Eichler, I. (1996) Relationship between disease severity and inflammatory markers in cystic fibrosis. Arch Dis Child, 75, pp. 498-501.
6. Zapletal, A., Samanek, M. and Paul, T. (1899) Progress in respiration research, Karger
7. Quanjer, PH, Tammeling, GJ, Cotes, JE, Pedersen, OF, Peslin, R. and Yernault, JC. (1993) Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl, 16, pp. 5-40.
8. Döring, G., Conway, SP, Heujerman, HGM, Hodson, ME, Høiby, N. and Smyth, A. (2000) Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: A European consensus. Eur Respir J, 16, pp. 749-767.
9. Govan, JRW and Deretic, V. (1993) Microbial pathogenesis in cystic fibrosis: Mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microb Rev, 60, pp. 539-543.
10. Høiby, N. (1982) Microbiology of lung infections in cystic fibrosis patients. Acta Paediatrica Scand Suppl, 301, pp. 33-54.
11. Rabin, HR, Butler, SM, Wohl, MEB, Geller, DE, Colin, AA and Schidlow, DV (2004) Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol, 37, pp. 400-406.
12. Olsson, I., Olofsson, T., Ohlsson, K. and Gustavsson, A. (1979) Serum and plasma myeloperoxidase, elastase and lactoferrin content in acute myeloid leukemia. Scand J Haematol, 22, pp. 397-406.
13. Olsen, RL and Little, C. (1983) Purification and some properties of myeloperoxidase and eosinophil peroxidase from human blood. Biochem J, 209, pp. 781-787.
14. Olsen, RL, Steigen, TK, Holm, T. and Little, C. (1986) Molecular forms of myeloperoxidase in human plasma. Biochem J, 237, pp. 559-565.
15. Redding, GJ, Restuccia, R., Cotton, EK and Brooks, JG. (1982) Serial changes in pulmonary functions in children hospitalized with cystic fibrosis. Am Rev Respir Dis, 126, pp. 31-36.
16. Regelmann, WE, Elliott, GR, Warwick, WJ and Clawson, CC. (1990) Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than does bronchodilators and chest physiotherapy alone. Am Rev Respir Dis, 141, pp. 914-921.
17. Bonfield, TL, Panuska, JR, Konstan, MW, Hilliard, KA, Hilliard, JB and Ghnaim, H. (1995) Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med, 152, pp. 2111-2118.
18. Rosenfeld, M., Emerson, J., Williams-Warren, J., Pepe, M., Smith, A. and Montgomery, B. (2001) Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr, 139, pp. 359-365.
19. Ramsey, BW and Boat, TF (1994) Outcome measures for clinical trials in cystic fibrosis. J Pediatr, 124, pp. 177-192.
20. Konstan, MW, Hilliard, KA, Norvell, TM and Berger, M. (1994) Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med, 150, pp. 448-454.
21. Sagel, SD, Sontag, MK, Wagener, JS, Kapsner, RK, Osberg, I. and Accurso, FJ. (2002) Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. J Pediatr, 141, pp. 811-817.
22. Ordonez, CL, Henig, NR, Mayer-Hamblett, N., Accurso, FJ, Burns, JL and Chmiel, JF (2003) Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med, 168, pp. 1471-1475.
23. Ordonez, CL, Kartashov, AI and Wohl, ME. (2004) Variability of markers of inflammation and infection in induced sputum in children with cystic fibrosis. J Pediatr, 145, pp. 689-692.